COMPANY
Transgene
Timeline
- Trial start Phase 1: A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) source ↗
- Trial start Phase 1/Phase 2: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors source ↗
- Trial start Phase 1/Phase 2: Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer source ↗
- Trial start Phase 1/Phase 2: A Clinical Trial Evaluating TG4050 in Head and Neck Cancer source ↗
- Trial start Phase 1: A Trial Evaluating TG4050 in Ovarian Carcinoma. source ↗
- Trial start Phase 1/Phase 2: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. source ↗
- Trial start Phase 2: A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cel source ↗
- Trial start I: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers source ↗
- Trial start Phase 1/Phase 2: A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment o source ↗
- Trial start Phase 1: Safety and Tolerability of TG1050: A Dose-finding Study source ↗
- Trial start Not phased (device or behavioral study): Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection source ↗
- Trial start IIB: Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients source ↗
- Trial start Phase 1: Trial of TG4023 Combined With Flucytosine in Liver Tumors source ↗
- Trial start Phase 1: Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus source ↗
- Trial start Phase 2: Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma source ↗
- Trial start Phase 2/Phase 3: Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer source ↗
Upcoming milestones
- Dec 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Clinical Trial Evaluating TG4050 in Head and Neck Cancer · NCT04183166
Clinical trials (lead sponsor) 18
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | I | Active, not recruiting | Sep 1, 2017 | Sep 18, 2024 (actual) |
| NCT04183166 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Phase 1/Phase 2 | Active, not recruiting | Dec 12, 2019 | Dec 30, 2027 (estimated) |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Phase 1/Phase 2 | Terminated | Feb 25, 2021 | Oct 22, 2025 (actual) |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Phase 1 | Completed | Dec 9, 2019 | Oct 8, 2024 (actual) |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Phase 1 | Terminated | Apr 5, 2023 | Jun 23, 2025 (actual) |
| NCT03724071 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Phase 1/Phase 2 | Terminated | Oct 16, 2018 | Feb 23, 2023 (actual) |
| NCT04194034 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | Phase 1/Phase 2 | Terminated | Jan 17, 2020 | Feb 23, 2023 (actual) |
| NCT03353675 | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Jan 5, 2018 | Nov 20, 2019 (actual) |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | Phase 1/Phase 2 | Terminated | Jul 27, 2017 | Sep 30, 2020 (actual) |
| NCT02428400 | Safety and Tolerability of TG1050: A Dose-finding Study | Phase 1 | Completed | 2015-10 | 2018-11 (actual) |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | IIB | Terminated | 2012-04 | 2015-07 (actual) |
| NCT02355951 | Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection | Not phased (device or behavioral study) | Completed | 2014-12 | 2016-02 (actual) |
| NCT00415818 | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | Phase 2/Phase 3 | Completed | 2005-12 | 2010-03 (actual) |
| NCT00394693 | Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma | Phase 2 | Completed | 2006-11 | 2010-01 (actual) |
| NCT00978107 | Trial of TG4023 Combined With Flucytosine in Liver Tumors | Phase 1 | Completed | 2009-09 | 2011-09 (actual) |
| NCT01055821 | Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients | Phase 2 | Completed | 2010-05 | 2012-10 (actual) |
| NCT00529321 | Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus | Phase 1 | Completed | 2006-12 | 2009-09 (actual) |
| NCT00040170 | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer | Phase 2 | Terminated | 2002-05 | Not listed |